stoxline Quote Chart Rank Option Currency Glossary
Bristol-Myers Squibb Company (BMY)
48.845  -0.075 (-0.15%)    11-29 11:02
Open: 49.06
High: 49.34
Volume: 2,114,605
Pre. Close: 48.92
Low: 48.835
Market Cap: 99,388(M)
Technical analysis
2023-11-29 10:45:40 AM
Short term     
Mid term     
Targets 6-month :  62.58 1-year :  66.3
Resists First :  53.58 Second :  56.77
Pivot price 50.05
Supports First :  48.41 Second :  40.28
MAs MA(5) :  49.22 MA(20) :  50.55
MA(100) :  57.8 MA(250) :  64.9
MACD MACD :  -1.6 Signal :  -1.6
%K %D K(14,3) :  12.1 D(3) :  15.8
RSI RSI(14): 34.1
52-week High :  81.44 Low :  48.41
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BMY ] has closed above bottom band by 25.6%. Bollinger Bands are 1.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 49.34 - 49.67 49.67 - 49.94
Low: 48.18 - 48.5 48.5 - 48.77
Close: 48.44 - 48.97 48.97 - 49.41
Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Headline News

Wed, 29 Nov 2023
BMY Factor-Based Stock Analysis - Nasdaq

Tue, 28 Nov 2023
Avidity Biosciences Announces Expansion of Cardiovascular ... - PR Newswire

Mon, 27 Nov 2023
What do the Fundamentals Predict for Bristol-Myers Squibb Co (BMY) Stock? - InvestorsObserver

Sun, 26 Nov 2023
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE? - Simply Wall St

Mon, 20 Nov 2023
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA ... - Bristol-Myers Squibb

Mon, 20 Nov 2023
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action ... - Morningstar

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—General
Shares Out 2,030 (M)
Shares Float 2,030 (M)
Held by Insiders 0 (%)
Held by Institutions 78.2 (%)
Shares Short 23,400 (K)
Shares Short P.Month 31,590 (K)
Stock Financials
EPS 3.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 14.26
Profit Margin 18.4 %
Operating Margin 19.1 %
Return on Assets (ttm) 5.5 %
Return on Equity (ttm) 26.8 %
Qtrly Rev. Growth -2.3 %
Gross Profit (p.s.) 17.92
Sales Per Share 22.13
EBITDA (p.s.) 9
Qtrly Earnings Growth 24 %
Operating Cash Flow 12,910 (M)
Levered Free Cash Flow 12,520 (M)
Stock Valuations
PE Ratio 12.43
PEG Ratio -26.3
Price to Book value 3.43
Price to Sales 2.21
Price to Cash Flow 7.7
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android